65,437 trials
Chronic Obstructive Pulmonary Disease (COPD)
Primary: Forced Expiratory Volume in One Second (FEV1), Peak Effect Within 0 - 24 Hours Post-dose — 1.67; 1.73; 1.64 L
Idiopathic Short Stature
Primary: Absolute On-target Difference (AOTD) at 24 Months — 0.603; 0.625 Standard Deviation Score (SDS) — p=0.5762
Carcinoma, Non-Small-Cell Lung
Primary: Phase I Step: Safety of BIBW 2992 Assessed Based on Incidence of Dose Limiting Toxicity (DLT) and Incidence & Intensity of Adverse Events According to CTCAE — 3; 3; 6; 3…
Cocaine Dependence
Primary: Cocaine Use Over Time — 0.01; 0.007; -0.01; 0.007 slope (change in prob of coc-pos utox/d) — p=<0.05
Gastroesophageal Reflux
Primary: Rate of Occurrence for Device and Procedure Related Serious Adverse Events (SAEs). — 6 participants
Amblyopia
Primary: Distribution of 10-week Amblyopic Eye Visual Acuity — 1; 0; 0; 0 participants
Cytomegalovirus Infection
Primary: Change in Best Ear Hearing Assessments at 6 Months. — 3; 5; 37; 36 participants
Schizophrenia · Schizoaffective Disorder · Schizophreniform Disorder
Primary: Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 104 or Last Reported Visit (LRV) — 80.6; 79.7; -18.1; -17.7 Units on a scale
Upper Respiratory Infections
Primary: Warming Sensation Caused by the Excipient IFF Flavor 316 282, in a Syrup Containing Paracetamol 500 mg + Phenylephrine 10mg + Guaifenesin 200 mg Per 30 ml Syrup — 34.6 mm
Epilepsy
Primary: Number of Participants With a >=50% Reduction in Partial-onset Seizure (POS) Frequency From Baseline — 22; 16; 22; 29 participants
Sickle Cell Anemia · Severe Aplastic Anemia · Paroxysmal Nocturnal Hemoglobinuria (PNH)
Primary: Number of Patients With Neutrophil Engraftment — 2 participants
Total Knee Replacement · Primary Knee Arthroplasty
Primary: Comparison of Postoperative Strength (Extension) — .08; .03; .05 Nm/kg
Healthy Subjects · Vitamin D Deficiency
Primary: hCAP18 Levels — 762; 639 ng/ml
Infection, Human Immunodeficiency Virus
Primary: Number of Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Ribonucleic Acid (RNA) <50 Copies/Milliliter (c/mL) at Week 16 — 51; 47; 46; 29 participants
Postoperative Hemorrhage
Primary: Mean Time to Hemostasis (TTH) — 1.9; 4.8 minutes — p=<0.001